Tools   Select Another Resource Report Type

http://obriencenter.yale.edu/mousecelllines.aspx

Core provides services to generate unique in vivo mouse models and kidney specific cell lines.

Proper citation: George M. O'Brien Kidney Center at Yale Mouse Genetics and Cell Line Core (RRID:SCR_015299) Copy   

•   Source: SciCrunch Registry
  

http://kidney.niddk.nih.gov

Information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established to increase knowledge and understanding about diseases of the kidneys and urologic system among people with these conditions and their families, health care professionals, and the general public: online, in booklets and fact sheets, by email, and over the phone. To carry out this mission, NKUDIC works closely with a coordinating panel of representatives from Federal agencies; voluntary organizations on the national level; professional groups; and State health departments to identify and respond to informational needs about kidney and urologic diseases. NKUDIC provides the following informational products and services: * Response to inquiries about kidney and urologic diseases-ranging from information about available patient and professional education materials to statistical data. By phone (8:30 a.m. to 5 p.m. eastern time, M-F), fax, mail, and email. * Publications about specific kidney and urologic diseases, provided free of copyright, in varying reading levels. Available online or as booklets and brochures. (See our Publications Catalog.) NKUDIC also sends publications to health fairs and community events. Please contact us for more information. * Referrals to health professionals through the National Library of Medicine''''s MEDLINEplus includes a consumer-friendly listing of organizations that will assist you in your search for physicians and other health professionals. * Exhibits at professional meetings specific to kidney and urologic diseases, as well as cross-cutting professional meetings. NKUDIC exhibits at 11 professional meetings, each year, including Society of Urologic Nurses and Associates, American Urologic Association, American Society of Nephrology, National Kidney Foundation, Polycystic Kidney Disease Research Foundation, American Academy of Family Physicians, American Academy of Physician Assistants, American Nurses Association, and the National Conference for Nurse Practitioners.

Proper citation: National Kidney and Urologic Diseases Information Clearinghouse (RRID:SCR_006842) Copy   

•   Source: SciCrunch Registry
  

http://www.kidneycenter.pitt.edu/cores/biostatistics.html

THIS RESOURCE IS NO LONGER IN SERVICE, documented on Feb 16, 2022. Core that offers biostatistical analysis to users of the Pittsburgh Center for Kidney Research. Available to the Pittsburgh Center for Kidney Research community.

Proper citation: Pittsburgh Center for Kidney Research Biostatistical Analysis Services (RRID:SCR_015290) Copy   

•   Source: SciCrunch Registry
  

http://www.mayo.edu/research/centers-programs/human-imaging-core/overview

Core provides semiautomated MRI and computed tomography (CT) image and volumetric analyses of polycystic kidneys and liver as well as functional assessment of the kidney and heart, including measurements of renal blood flow. It also facilitates the transmission, collection and storage of anonymized imaging data used in translational PKD research and provides a system that enables PKD researchers to exchange images.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester Human Imaging Core (RRID:SCR_015304) Copy   

•   Source: SciCrunch Registry
  

http://www.asn-online.org/khi/

Consortium that brings together the kidney community (patient advocacy groups, industry, government agencies, and professional organizations) to overcome existing challenges, including regulatory and nonregulatory barriers, and optimize the development and safety of products that impact kidney health including drugs, devices, biologics, and food products. The goals of the consortium are to: * Facilitate dialogue and research that informs regulatory processes with regard to the kidney health of patients being treated for kidney-related as well as other diseases. * Assess current medical therapies and diagnostics to identify areas in need of greater innovation and/or better defined regulatory pathways. * Develop innovative and efficient trial designs appropriate to answer the most important questions related to kidney health. * Establish expert consensus around common terminology and key definitions related to kidney health. * Develop approaches to the systematic collection of retrospective or prospective data, such as registries and/or global databases, and establishment of data standards. * Coordinate think tanks, public forums, educational exchanges, and other events to promote discussion and updates on topics in kidney health pertaining to drug, device, biologics, and food product development and evaluation. * Create transparent infrastructure and processes that facilitate collaboration and communication among the greater nephrology community and the FDA, including: * Seek input from all stakeholders (including nephrologists and other health professionals, patient groups, industry, the National Institutes of Health, the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, and other federal agencies). * Leverage previously conducted and ongoing clinical studies, research infrastructure, and databases. * Create an open and efficient mechanism for encouraging and objectively evaluating potential projects submitted to KHI. * Involve consortium members in the selection and execution of projects. * Establish systems to optimize post-market surveillance of products that affect kidney health, either intentionally or via adverse drug reactions. * Author journal articles and white papers regarding key issues, describing opportunities and challenges and proposing solutions, as well as promoting execution of these solutions.

Proper citation: Kidney Health Initiative (RRID:SCR_003869) Copy   

•   Source: SciCrunch Registry
  

https://www.niddk.nih.gov/research-funding/research-programs/kidney-disease-centers

A portal with detailed information about various research centers that focus on kidney disease and translational research funded by NIDDK.

Proper citation: Polycystic Kidney Disease Research and Translation Centers (RRID:SCR_015305) Copy   

•   Source: SciCrunch Registry
  

http://datahub.io/dataset/kupkb/resource/8c1e0082-e958-493b-83e6-111bc1c2f0a5

Ontology describing kidney and urinary pathways cell, anatomy, and disease.

Proper citation: Kidney and Urinary Pathway Ontology (RRID:SCR_006690) Copy   

•   Source: SciCrunch Registry
  

https://public.tableau.com/app/profile/ukkidney/viz/AKIlandingpage/Landingpage

UK Renal Registry collection of data from acute kidney injury patients in England.

Proper citation: Acute Kidney Injury Data Portal (RRID:SCR_024407) Copy   

•   Source: SciCrunch Registry
  

http://www.kidneycenter.pitt.edu/cores/model_organisms.html

Core that uses the yeast S. cerevisiae and the zebrafish D. rerio to dissect fundamental aspects of kidney development and protein structure and function.

Proper citation: Pittsburgh Center for Kidney Research Model Organisms (RRID:SCR_015288) Copy   

•   Source: SciCrunch Registry
  

http://eagle-i.ea.vanderbilt.edu/i/00000139-2ff7-d10c-dacb-da6080000000

The objectives of the physiology core are to establish average values and normal ranges for physiologic parameters of renal function in mice, and to develop novel assays of mouse kidney structure and function. Our goal is to provide valuable institutional and national shared resources to facilitate better understanding of kidney diseases and treatments.

Proper citation: Vanderbilt Mouse Kidney Physiology Core Lab (RRID:SCR_010193) Copy   

•   Source: SciCrunch Registry
  

https://www.uab.edu/medicine/obriencenter/cores/clinical-studies-of-aki-core

Core facility which provides investigators access to patients with AKI through an established international network of collaborating investigators. It also provides core resources to support the design and conduct of clinical research in AKI and genomics resources to perform systematic genomic analyses and allow correlation with clinical phenotypic information.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Clinical Studies of AKI (RRID:SCR_015287) Copy   

•   Source: SciCrunch Registry
  

https://www.niddk.nih.gov/research-funding/research-programs/kidney-disease-centers

Research program whose aim is to make state-of-the art technologies and resources accessible to a broad spectrum of investigators pursuing studies in kidney research areas.

Proper citation: O'Brien Kidney Centers (RRID:SCR_015270) Copy   

•   Source: SciCrunch Registry
  

http://obriencenter.yale.edu/

Center that facilitates translational and clinical research that will advance the prevention and treatment of kidney diseases.

Proper citation: George M. O'Brien Kidney Center at Yale (RRID:SCR_015294) Copy   

•   Source: SciCrunch Registry
  

http://www.baltimorepkdcenter.org/clinical/index.shtml

Core facility that provides clinical applications and methods to make kidney research translational and applicable to care settings.

Proper citation: Baltimore Polycystic Kidney Disease (PKD) Research and Clinical Core Center Clinical and Translational Core Resource (RRID:SCR_015291) Copy   

•   Source: SciCrunch Registry
  

http://c-path.org/programs/pkd/

Consortium to develop evidence supporting the use of imaging Total Kidney Volume (TKV) as a prognostic biomarker that predicts the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to select patients likely to respond to therapy into clinical trials. It aims to replace the currently used measurement of glomerular filtration rate (GFR). Scientists will use the data collected to develop a disease progression model that will evaluate the relationship between TKV and the known complications of ADPKD, including rate of loss of kidney function, hypertension, gross hematuria, kidney stones, urinary tract infections, development of end-stage renal disease, and mortality. These analyses will be used to support the regulatory qualification of TKV as an accepted measure for assessing the progression of ADPKD in clinical trials in which new therapies are tested. PKDOC has the following goals: # Develop standard clinical data elements and definitions that are specific to ADPKD # Create a database of aggregated data from existing multiple, longitudinal, and well-characterized research registries maintained over decades by the leading institutions in ADPKD clinical investigation # Advance and harmonize the missions of regulatory agencies by creating tools that help with the evaluation of new pharmaceutical compounds # Develop a quantitative disease progression model to examine the linkage between TKV and disease outcomes

Proper citation: Polycystic Kidney Disease Outcomes Consortium (RRID:SCR_003674) Copy   

•   Source: SciCrunch Registry
  

http://www.cng.fr/cagekid

The Cancer Genomics of the Kidney (CAGEKID) consortium brings together expertise in clinical care and epidemiology with genomic expertise. This consortium is an effort of the larger International Cancer Genome Consortium (ICGC), which has the goal of obtaining a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumour types and/or subtypes with the aim of elucidating the genomic changes present in the many forms of cancers that contribute to the burden of disease throughout the world.

Proper citation: Cancer Genomics of the Kidney (CAGEKID) (RRID:SCR_013670) Copy   

•   Source: SciCrunch Registry
  

http://www.baltimorepkdcenter.org/antibody/index.shtml

Core which supports the work of the Baltimore Polycystic Kidney Disease research center by providing antibody validation services and vectors to researchers.

Proper citation: Baltimore Polycystic Kidney Disease (PKD) Research and Clinical Core Center Antibody Validation and Vector Core (RRID:SCR_015318) Copy   

•   Source: SciCrunch Registry
  

http://archives.niddk.nih.gov/patient/crisp/rp-crisp.aspx

A five-year prospective cohort study following 240 patients who have autosomal-dominant polycystic kidney disease (PKD) to determine whether changes in anatomic characteristics of their kidneys as measured by magnetic resonance imaging will be useful in providing surrogate measures for disease progression. CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. Specific goals of this study are to: * Quantify cyst growth and ascertain severity of renal parenchymal involvement by sequential measurement of total kidney volume and the ratio of intact parenchyma to renal parenchyma occupied by cysts over time * Establish useful clinical correlations of imaging data with other markers of disease progression * Identify and test other potential markers or indices of disease progression, for example, assessment of loss of heterozygosity of renal cells shed in the urine, or other markers, in cohorts of patients with PKD * Gain information about the cost-effectiveness, patient acceptability, and advantages and disadvantages of different imaging techniques used serially in patients with PKD. Some experience has been gained in establishing that repeat imaging of the same PKD patient, using these techniques, yields reproducible estimates of kidney size and the proportion of renal parenchyma occupied by cysts. MRI may also have the advantage of permitting simultaneous estimation of GFR. Ultrasound has the advantage of being more cost-effective and perhaps more acceptable to patients for repetitive studies, but the measurements may be less accurate and reproducible. Nonetheless, there is very limited experience in applying these techniques to follow progression of the renal disease. Development of improved, reproducible imaging methods that assess cyst growth and provide markers of disease progression could markedly improve the feasibility of clinical trials. Participating clinical centers are Emory University, the Mayo Clinic, University of Kansas, and the University of Alabama at Birmingham. The data coordinating and imaging analysis center is at Washington University. (PI has since moved to University of Pittsburgh) The study found that kidney enlargement resulting from the expansion of cysts is continuous, quantifiable, and associated with the decline of renal function. Cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid decrease in renal function. These anatomic characteristics of patient kidneys may provide useful surrogate measures for disease progression, and hence enhance the development of targeted therapies for autosomal dominant PKD. CRISP III is a five-year prospective cohort study to follow ~170 remaining autosomal dominant polycystic kidney disease (ADPKD) patients who were part of the original CRISP cohort study. CRISP III will verify and extend the preliminary observations of CRISP to determine the extent to which quantitative (kidney volume and blood flow, and hepatic and kidney cyst volume) or qualitative (cyst distribution and character) structural parameters predict renal insufficiency and develop and test new metrics to quantify and monitor disease progression. Urine metabolites and the genome will be correlated with the progression of disease to look for new, predictive disease biomarkers. This information from CRISP III will help determine if the kidney enlargement, blood flow, cyst distribution, or urine metabolites can function as an informative surrogate measure for disease progression.

Proper citation: Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (RRID:SCR_000690) Copy   

•   Source: SciCrunch Registry
  

http://www.dukekidneycenter.org/cores/renal-genomics-core

Core facility that provides resources for investigators researching the genetic mechanisms of chronic kidney disease, cardiovascular disease, and hypertension. Its services include pre-study consultation, standardized services for DNA isolation and storage, and assisstance in carrying out molecular genetic studies.

Proper citation: Duke O'Brien Center for Kidney Research Renal Genomics Core (RRID:SCR_015269) Copy   

•   Source: SciCrunch Registry
  

http://www.mayo.edu/research/centers-programs/translational-polycystic-kidney-disease-pkd-center/overview

Center that concentrates on the common, adult form of the disease, autosomal dominant PKD (ADPKD). The services provided focus on understanding the genetic basis of disease, more accurately monitoring disease progression and improving prognostics, and employing model systems to explore pathogenesis and conduct preclinical testing.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester (RRID:SCR_015313) Copy   

•   Source: SciCrunch Registry